MORRISON & FOERSTER

SAN FRANCISCO LOS ANGELES SACRAMENTO ORANGE COUNTY WALNUT CREEK SEATTLE ATTORNEYS AT LAW

755 PAGE MILL ROAD
PALO ALTO, CA 94304-1018
TELEPHONE (415) 813-5600
TELEFACSIMILE (415) 494-0792
TELEX 706141 CIOTTI UD

NEW YORK
WASHINGTON, D.C.
DENVER
LONDON
BRUSSELS
HONG KONG
TOKYO

November 22, 1995

DIRECT DIAL NUMBER

(415) 813-5730

By Messenger

Mr. Gerald Dost U.S. Patent and Trademark Office Patent Term Extension Application Branch Washington, D.C. 20231 RECEIVED

NOV 2 4 1995

OFFICEUPPETITIONS

Re: New U.S. Patent Application

For: Application for Patent Term Extension for U.S. Patent No.

4,983,395

By: Yunik Chang

Our reference: 29065-28024.00

Dear Mr. Dost:

Enclosed is an Application for Patent Term Extension for Patent No. 4,983,395, including a certified copy of the application, three working copies, transmittal letter, check in the amount of \$1,060.00, and postcard. The sixty day statutory deadline expires for this application on **November 28, 1995.** If you have any questions or comments, please contact me at the above number.

Sincerely,

Antoinette F. Konski

Enclosures

111-106000

Docket No. 290652802400

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Yunik Chang et al.

Serial No.:

07/326,536

Filing Date:

March 21, 1989

Patent No.:

4,983,395

Issued:

January 8, 1991

DEVICE FOR ADMINISTERING

AN ACTIVE AGENT TO THE SKIN OR

MUCOSA

Sir:

NOV: 2 4 1995

TRANSMITTAL LETTER

Assistant Commissioner for Patents and Trademarks **Box Patent Extension** Washington, D.C. 20231

Enclosed are the following:

- 1. Application for Extension of Patent Term Under 35 U.S.C. Section 156.
- 2. A Certified Duplicate Application for Extension of Patent Term Under 35 U.S.C. Section 156.

- 3. Three (3) Working Copies of Application for Extension of Patent Term Under 35 U.S.C. Section 156.
 - 4. A check in the amount of \$1,060.00.

In the unlikely event that this transmittal letter is separated from this document and the Patent Office determines that an additional fee is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing these papers to Deposit Account No. 03-1952.

Respectfully submitted,

Antoinette F. Konski Registration No. 34,202

Date: November 22, 1995

MORRISON & FOERSTER 755 Page Mill Road Palo Alto, CA 94304-1018 (415) 813-5600

Fax: (415) 494-0792

CERTIF1CATE	OF	HAND	DELIVE	RY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on November 24, 1995.

Singed:	 _
Printed Name:	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Yunik Chang et al.

Serial No.:

07/326,536

Filing Date:

March 21, 1989

Patent No.:

4,983,395

Issued:

January 8, 1991

For:

DEVICE FOR ADMINISTERING

AN ACTIVE AGENT TO THE SKIN OR

MUCOSA

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. SECTION 156

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231

Dear Sir:

In accordance with 35 U.S.C. Section 156, Applicant TheraTech, Inc. a corporation of the State of Delaware, having a place of business at 417 Wakara Way, Suite 100, Salt Lake City, Utah, 84108, (hereinafter "TheraTech") represents that it is the assignee of the entire interest in and to Letters Patent of the United States No. 4,983,395, granted to Yunik Chang, Dinesh C. Patel, and Charles D. Ebert for DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA by virtue of an assignment in favor of TheraTech, recorded on March 21, 1989, on Reel

5056, Frame 0212, and by virtue of an assignment for U.S. Patent No. 4,849,224, filed November 12, 1987, directed to DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA, recorded on December 28, 1987, on Reel 4802, Frame 0996. See Appendix Tab A for copies of the assignment documents identified above.

This application is submitted by Applicant's authorized agent as set forth in 37 C.F.R. Section 1.730. See Appendix Tab B for a copy of the Power of Attorney authorizing the undersigned to act in this manner. Applicant hereby submits this application for extension of patent term under 35 U.S.C. Section 156 by providing the following information as set forth in 37 C.F.R. Section 1.740.

- (1) The approved product is identified as Androderm® that is used for the transdermal administration of testosterone.
- (2) The approved product was subject to regulatory review under Section 505(b) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. Section 360(e)).
- (3) The approved product received permission for commercial marketing and use under Section 505(b) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. Section 360(e)) on September 29, 1995.
- (4) This Application for extension of the patent term under 35 U.S.C. Section 156, is being submitted within the statutory 60 day period, said period to expire on November 28, 1995.

(5) The complete identification of the patent for which extension is being sought is as follows:

Inventors:

Yunik Chang, Dinesh C. Patel, and Charles D. Ebert

Patent No.:

4,983,395

Issue Date:

January 8, 1991

Expires:

July 18, 2006 (17 year patent term minus the term lost due to terminal

disclaimer) or November 12, 2007 (20 years from the earliest filing date claimed under 35 U.S.C.

Section 120).

(6) See Appendix Tab C for a copy of the patent identified in Paragraph 5, above.

(7) A receipt of maintenance fee payment has been issued with regard to U.S. Patent No. 4,983,395. A copy of the maintenance fee receipt is attached as Appendix Tab D.

(8) A copy of the terminal disclaimer filed in connection during the prosecution of U.S. Patent No. 4,983,395 is attached as Appendix Tab E. No reexamination certificate or Certificate of Correction has been issued in connection with U.S. Patent No. 4,983,395.

STATEMENT PURSUANT TO 37 C.F.R. 1.740(a)(9)

(9) U.S. Patent No. 4,983,395, claims the approved product Androderm. The product is manufactured as a closed system that when opened, is ready for application by a patient. The product consists of a gel reservoir, that is formed between an impermeable backing film and a microporous membrane. The gel reservoir contains the active agent --testosterone and skin permeation enhancers. On one side of the reservoir is an active agent impermeable, ethylene vinyl acetate copolymer/polyester laminate backing film. On the opposite side of the reservoir are several layers. The first layer lies adjacent to the reservoir; it is a microporous membrane. Adjacent to the microporous membrane is a peelable disk that serves to isolate the reservoir gel from the reservoir from the adhesive. The peel-seal disk provides product stability by preventing migration of the reservoir gel components into the peripheral adhesive over prolonged storage. The pressure sensitive adhesive layer is positioned below and around the periphery of the peelable disk. A second, separate adhesive layer is positioned directly below the peelable disk layer. The final layer is the release liner.

Claims 1 through 6 describe a device for administering an active agent such as testosterone (column 5, lines 14 and 15, of the patent) to the skin or mucosa of an individual. Claims 1 through 3, embrace the product Androderm®. The manner in which each applicable patent claim reads on the approved product is as follows:

<u>Claim 1</u> of U.S. Patent No. 4,983,395, claims a laminated composite comprising:

- a) a backing layer;
- b) an active agent-permeable membrane, the backing and membrane defining
- c) a reservoir therebetween that contains a formulation of the active agent, said reservoir having a smaller periphery than the backing layer and membrane such that a portion of the backing layer and membrane extends outwardly of the periphery of the reservoir;

4

Application for Patent Extension Patent No.: 4,983,395 Issued: January 8, 1991 Atty Dkt No 290652802400

- d) a first peelable active agent formulation-impermeable layer that underlies the reservoir and a portion of said outwardly extending portion of the backing layer and membrane;
- e) an adhesive layer that underlies and covers the first peelable active agent formulation-impermeable layer and said outwardly extending portion of the backing layer and membrane;
- f) a second peelable active agent formulation-impermeable layer that underlies and covers the adhesive layer;
- g) a permanent heat seal about the periphery of the reservoir between the backing layer and the membrane; and
- h) a peelable heat seal between the membrane and the first peelable active agent formulation-impermeable layer located underneath and at a radius not less than that of the permanent heat seal, said permanent and peelable heat seals providing barriers to migration of components of the active agent formulation from the reservoir into the adhesive layer and said first and second peelable active agent impermeable layers being bonded together such that when the second peelable layer is removed from the device, the peelable heat seal is broken and the first peelable layer and underlying portion of the adhesive layer is removed therewith.

Androderm® contains a backing layer (element (a) of claim 1), the microporous membrane lying below and defining the gel reservoir (element (b) of claim 1), the reservoir into which the active agent testosterone and permeation enhancers are initially loaded (element (c) of claim 1), a first peelable active agent formulation-impermeable layer that underlies the reservoir that lies underneath the reservoir which extends beyond the periphery of the reservoir (element (d) of claim 1), an adhesive layer that lies underneath the first peelable active agent formulation (element (e) of claim 1), a release liner that serves as a second peelable active agent formulation-impermeable layer that underlies and covers the adhesive layer (element (f) of claim 1), two heat seals, the first heat seal between the membrane and the first peelable active agent-impermeable

layer (element (h) of claim 1) and the second about the periphery of the reservoir (element (g) of

claim 1). Therefore, claim 1 embraces Androderm®.

Claim 2 of U.S. Patent No. 4,983,395, is to the device of claim 1, wherein the adhesive is

incompatible with one or more of the components of the formulation that permeate through and

an inner heat-sealable layer. Pressure sensitive adhesives used in transdermal application are not

stable in contact with permeation enhancers, and do become plasticized and ineffective. Thus,

the pressure sensitive adhesive utilized around the periphery of the reservoir to adhere the device

to the skin is incompatible with the permeation enhancer in the formulation initially loaded into

the reservoir. Thus, Androderm® embraces claim 2 of U.S. Patent No. 4,983,395.

<u>Claim 3</u> claims the device of claim 1 wherein the backing layer is a laminated composite

of at least one layer that is impermeable to the formulation and an inner heat sealable layer.

Androderm® contains the peel seal disc that is impermeable to the formulation and an inner heat

sealable layer. Therefore, claim 3 embraces the product Androderm®.

6

Application for Patent Extension Patent No.: 4,983,395 Issued: January 8, 1991

Atty Dkt No 290652802400

pa-51171

STATEMENT PURSUANT TO 37 C.F.R. SECTION 1.740(a)(10)

- (10) The relevant dates and information pursuant to 35 U.S.C. Section 156(g), to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:
- (a) As shown in Appendix Tab F, the application under subsection (i) of Section 505(b) of the Federal Food, Drug and Cosmetic Act for an Investigational New Drug Application for Androderm® was received on November 28, 1989. Receipt was acknowledged on December 1, 1989.
- (b) As shown in Appendix Tab F, the date the application with respect to the human drug product under Section 505(b) of the Federal Food, Drug, and Cosmetic Act was received September 30, 1994.
- (c) The application was approved by the Food and Drug Administration on September 29, 1995.

STATEMENT PURSUANT TO 37 CFR §1.740(a)(11)

(11) As a brief description of the activities undertaken by the marketing applicant, TheraTech, during the applicable regulatory review period as set forth in 37 CFR §1.740(a)(11), is set forth in Appendix Tab F, as a chronology of the major communications between TheraTech and the FDA from about November 28, 1989 until about September 29, 1995.

STATEMENT PURSUANT TO 37 CFR §1.740(a)(12)

- (12) Applicant is of the opinion that U.S. Patent No. 4,893,395, is eligible for extension under 35 U.S.C. Section 156, whether patent term is measured seventeen (17) years from date of issue minus any term disclaimed or twenty (20) years from the earliest filing date claimed under 35 U.S.C. Section 120, because it satisfies all the requirements for such extensions as follows:
 - (a) 35 U.S.C. Section 156(a)
 U.S. Patent No. 4,893,395, claims a drug delivery device embodied by Androderm®.
 - (b) 35 U.S.C. Section 156(a)(1)

 The term of U.S. Patent No. 4,983,395, has not expired before submission of this application.
 - (c) 35 U.S.C. Section 156(a)(2)

 The term of U.S. Patent No. 4,983,395, has never been extended.
 - (d) 35 U.S.C. Section 156(a)(3)

 The application for extension is submitted by TheraTech, the assignee of the entire interest of U.S. Patent No. 4,983,395. See Appendix Tab A.
 - (e) 35 U.S.C. Section 156(a)(4)

 The product, Androderm® has been subject to a regulatory review period before its commercial marketing or use.
 - (f) 35 U.S.C. Section 156(a)(5)(a)

 The commercial marketing or use of the product, Androderm® after the regulatory review period is the first permitted commercial marketing or use of the product under the provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 355) under which such regulatory period occurred.

- (13) The length of extension of the patent term of U.S. Patent No. 4,983,395, claimed by TheraTech is 2.25 years or 820 days. The length of the extension was determined as follows:
- (a) The regulatory review period under 35 U.S.C. Section 156(g)(3)(A) as set forth in 37 CFR Section 1.775, is sum of: a) the period beginning on the date an exemption under subsection (i) of Section 505 of the Federal Food, Drug, and Cosmetic Act became effective for the approved product and ending on the date the application was initially submitted for such product; and b)the number of days in the period beginning on the date the application was initially submitted for the approved product under Section 351 of the Public Health Service Act, subsection (b) of the Federal Food, Drug, and Cosmetic Act and ending on the date such application was approved under such Section. The applicable number of days for Androderm® for this period is 2101 days or 5.8 years, which began on November 28, 1989 and ending about September 29, 1995.
- (b) The regulatory review period upon which the period of extension is calculated is the entire regulatory review period as determined in sub-paragraph 13(a) above (365 days) less the sum of:
- (i) The number of days in the regulatory period as set forth in §1.775(c)(1) and (2) which were on and before the date on which the patent issued, which is 461 days (i.e., from November 28, 1989 to January 8, 1991);
- (ii) The number of days in the regulatory period as set forth in $\S1.775(c)(1)$ and (2) during which TheraTech, did not act with due diligence, which is zero (0) days (365 0 = 365); and
- (iii) One-half the number of days remaining in the period as set forth in $\S1.775(c)(1)$ after that period is reduced in accordance with paragraphs (d)(1)(i) and (ii), which is $(1640 \div 2 = 820 \text{ days or } 2.25 \text{ years})$;
- (c) The number of days as determined in 13(b) above, that is, 820 days or 2.25 years, when added to the original term of the patent that is July 18, 2006 or November 12, 2007, would result in the date October 16, 2008 or February 10, 2009, respectively.

- (d) The addition of fourteen (14) years to the date of approval of the application under Section 351 of the Federal Food, Drug and Cosmetic Act would result in the date September 29, 2009.
- (e) When comparing 13(c) and (d) above, the earlier date is either of October 16, 2008 or February 10, 2009.
- (f) Since the original patent issued after September 24, 1984, and since no request for exemption under subsection (i) of §505 of the Federal Food, Drug and Cosmetic Act was submitted before September 24, 1984, five (5) years when added to the original expiration date of the patent would result in the dates of July 18, 2011 (17 year patent term) or November 12, 2012 (20 year patent term).
- (g) The earlier date when comparing 13(c) and (f) above is either of October 16, 2008 or February 10, 2009.

Therefore, the length of extension of patent term claimed by TheraTech is 820 days or 2.25 years.

STATEMENT PURSUANT TO 37 CFR §1.740(a)(13)

- (14) Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services any information which is material to any determinations to be made relative to the application for extension.
- (15) The prescribed fee for receiving and acting upon this application is enclosed. If any additional fees are due, authorization is given to charge our deposit account number 03-1952.
 - (16) Direct all inquiries and correspondence relating to this application to

Antoinette F. Konski

Morrison & Foerster 755 Page Mill Road Palo Alto, CA 94304 Phone: (415) 813-5730 Fax: (415) 494-0792

(17) A certified duplicate of this application is being submitted herewith.

(18) The requisite declaration pursuant to 37 CFR §1.740(b) is attached hereto as Appendix Tab G.

Respectfully submitted,

Antoinette F. Konski Registration No.:34,202

Date: November 22, 1995

Morrison & Foerster 755 Page Mill Road Palo Alto, CA 94304-1018 (415) 813-5600

Fax: (415) 494-0792



UNITED STATES ARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231



TO: IRELL & MANELLA

545 MIDDLEFIELD ROAD, STE. 200

MENLO PARK, CA 94025-3471

OCT 6 1989

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: 001 CHANG, YUNIK

ASSIGNOR: 002 PATEL, DINESH C.

ASSIGNOR: 003 EBERT, CHARLES D.

DOC DATE: 03/17/89

DOC DATE: 03/16/89

DOC DATE: 03/16/89

RECORDATION DATE: 03/21/89 NUMBER OF PAGES 001 REEL/FRAME 5056/0212

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE: 501 THERATECH, INC., RESEARCH PARK, 410 CHIPETA WAY, STE. 219

, SALT LAKE CITY, UT 84108, A CORP. OF UT

SERIAL NUMBER 7-326536

PATENT NUMBER

FILING DATE 03/21/89
ISSUE DATE 00/00/00

TITLE OF INVENTION: DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SK

IN OR MUCOSA

INVENTOR: 001 CHANG, YUNIK

INVENTOR: 002 PATEL, DINESH C.

INVENTOR: 003 EBERT, CHARLES D.

DOCKETED TEC 9065-0003 20

Application for Patent Extension Patent No. 4,983,395

Atty Dkt.: 290652802400

Appendix A

A 700 578 American Decided No. 9065-0003.29



IRELL & MANELLA 545 Middleffeld Road, Suite 200 Menio Park, California 94025-3471

17/326536

APPLICATION TRANSMITTAL LETTER

		· · · · · · · · · · · · · · · · · · ·	
Sir:		REC	
Transmit	tted herewith for filing is the patent application	- A (FI)	
of Yunik Ch	ang, Dinesh C. Patel, Charles	D. Ebert	
forDEVICE :	FOR ADMINISTERING AN ACTIVE A	AGENT TO THE SKIN OF MUCCOS	
Enclosed		- Super Odymocosa	
X _	2 sheet(s) of formal informal draw	wing(s). (3 sets)	
	claim for foreign priority under 35 U.S.C. §119	CERTIFICATE OF MAILING BY "EXPRESS Express Mail" Mailing Label No MBI CO193	MAL
	a separate document the declarate		
	cartified copy of the priority document.	with the United Frates the self-self-self-self-self-self-self-self-	
☐ Ar	Associate Power of Attorney.	Patents and Traditionals a Markhaghas (1967) wh	
	verified statement(s) of small entity statu	(Typed or Printed Mame of Persons Holling Page	r or F
The declar	ation of the inventor is enclosed will fo	Doute M. Tax	
The fee ha	s been calculated as follows:	(Signature of Person Meiling Paper or Fee)	
	sic Application Fee		
	tal Claims6_ minus 20 =	\$ 340.00	
	ependent	x \$ 12.00 = \$	
	ims1 minus 3 =0	x \$ 34.00 = \$ -0-	
D. _. lf m	ruitiple dependent claims present, add	\$ 110.00 = \$	
	al Application Fee (Total of A, B, C, & D)	340.00	
F. If ve	Prified statement of small entity status is application		
	percent reduction of Total Application Fee % x E)	_ • -0-	
G. App	fication Fee Due (E minus F)	\$ 340.00	
H. Assi	ignment Recording Fee of \$7.00 if assignment	<u> </u>	
		- \$	
	'AL FEE (G plus H)	\$ 347.00	
_	eck in the amount of \$ 347.00 is attached		
☐ Char	rge \$ to Deposit Account No. 03	3-1 952.	
The Commis	sioner is hereby authorized to charge any feet of by this paper, or to credit any overpayment, sheet is enclosed.		
	/\$BignomEH6t Branch 1 51	_	
	1 21	9 / 1.90 CK	
	By	Monus E. Carth	

ASSIGNMENT

JOINT

			esh C. Patel, (maries D. Ebe	rt,
		· · · ·			
(hereinatter referr	ed to as the assigno	ors), residing at T	oms River, New	Jersey: Murra	V. Iltah
Salt Lake	City, Utah	and Salt La	ke City, Utah		y , o can;
respectively, witne			2,7 000		
WHERE	AS, the said assigne	are have taken			
FOR ADMIN	ISTERING AN	A CONTERN A CON	rtain new and useful impro	vements in DEVICE	
cot forth in	TOTAL AN	ACTIVE AGE	NT TO THE SKIN	OR MUCOSA	
Set forth in an appl	ication for Letters P.	atent of the United S	itates, X having an oath	or declaration executed	on even
date herewith;	bearing Serial No.		and filed or	n:	
WHEREA	S. <u>TheraTe</u>	ech, Inc.			and
duly organized und	er and pursuant to the	the laws ofUt	ah	and having its as	::
place of business a	Research I	Park, 410 Ch	ipeta Way, Sui	te 219 Salt T	ncipai nko
			iring the entire right, title a led States, and in and to a		
ver, and by these pives and assigns, the atent, and any and be granted therefor a pplication, or reissue on for the Protection and behoof and the Larms for which Letter and enjoyed by the a AND for the ssignee, its success resents, the said as versions and the apaid assignors have girth.	presents do sell, ass ne entire right, title a la la latters Patent o and thereon, and in use or extensions of no of Industrial Propeuse and behoof of its assignors, had this a same consideration sors, legal represent signors are the sole opplication for Letters good and full right a	sign, transfer and set and interest in and to or Patents in the United and to any and all did said Letters Patent is successors, legal in the said assignment in, the said assignors fatives and assigns, and lawful owners of Patent abovementic ind lawful authority to in, the said assignors in, the said assignors	thereby covenant and agrithat, at the time of execution the entire right, title and oned, and that the same as a self and convey the same hereby covenant and agrithereby covenant and agrithments.	issigned, transferred and issuccessors, legal reputions, application for Leal foreign countries while discontinuations-in-part of independent of the international Card assignee, for its own is, to the full end of the iname would have been here to and with the said ion and delivery of these interest in and to the said in the manner herein set in the manner herein set.	d set resenta- itters ch may f said onven- use derm or neid
AND for the ssignee, its success ssignee, or the coun onnection with said if atent for said inventivision, continuation of the said in the said invention of the said in the s	nsel of its successor Inventions, or said a tions in any country, or continuation-in-pobtained thereon, is	re, legal representations polication for Letters including interference out of any applications lawful and desirable	was and assigner, shall adves and assigner, shall adves Patent, or any proceedings proceedings, is lawful and for Letters Patent, or any or sign alf papers and docu	t, whenever counsel of the that any proceeding of the connection with Let on desirable, or that any reissue or extension of the country of th	et he said in ters y any
AND for the ssignee, its success ssignse, or the coun panedlen with sald attent for said invent vision, continuation afters Patent, to be of do all acts necessitiers Patent for said isigns, but at the countries of the said and of states to the said and of states to the said inded States to the said signs, but at the said and of states to the said states to the said states to the said said said said said said said said	nsel of its successor inventions, or said a tions in any country, or continuation-in-pobtained thereon, is sary or required to be dinventions, without at and expense of the diassignors hereby it aid assignors as the said as the said assignors as the said as the sa	re, legal representative application for Letters, including interference including interference is awful and desirable be done for the procut charge to the said assignee, its request the Commissions.	ves and assigne, shell edves and assigner, shell edves Patent, or any proceedings proceedings, is lawful an for Letters Patent, or any p., sign alf papers and docuprement, maintenance, end assignee, its successors, legal represessioner of Patents to issue	f, whenever counsel of the that any proceeding in connection with Let and desirable, or that any reissue or extension of the that any reissue or extension of the that are that are the that are the that are that ar	et he said in lers y any aths, of
AND for the ssignee, its success ssignse, or the coun panedlen with sald attent for said invent vision, continuation afters Patent, to be of do all acts necessitiers Patent for said isigns, but at the countries of the said and of states to the said and of states to the said inded States to the said signs, but at the said and of states to the said states to the said states to the said said said said said said said said	nsel of its successor inventions, or said a tions in any country, or continuation-in-pobtained thereon, is sary or required to be dinventions, without at and expense of the diassignors hereby it aid assignors as the said as the said assignors as the said as the sa	re, legal representative application for Letters, including interference including interference is awful and desirable be done for the procut charge to the said assignee, its request the Commissions.	ves and assigne, shell edves and assigner, shell edves Patent, or any proceedings proceedings, is lawful an for Letters Patent, or any p., sign alf papers and docuprement, maintenance, end assignee, its successors, legal represessioner of Patents to issue	f, whenever counsel of the that any proceeding in connection with Let and desirable, or that any reissue or extension of the that any reissue or extension of the that are that are the that are the that are that ar	et he said in lers y any aths, of
AND for the signee, its success signee, or the cour namedle with said invent vision, continuation atters Patent for said invent vision, continuation atters Patent, to be on the said of all acts necessities Patent for said inters patent for said inters.	nsel of its successor Inventions, or said a tions in any country, or continuation-in-pobtained thereon, is sary or required to be dinventions, without st and expense of the diassigners hereby it aid assignee as the cof of the said assigned.	re, legal representative polication for Letters, including interference including interference in a series of any application is lawful and desirable be done for the procest charge to the said assignee, its request the Commission assignee of said invinee, its successors,	ves and assigner, shell edvis Patent, or any proceedings, is lawful a nifer Letters Patent, or any proceedings, is lawful a nifer Letters Patent, or any p., sign all papers and document, maintenances, is successors, legal represessioner of Patents to issue rentions and the Letters Palegal representatives and	t, whenever counsel of the that any proceeding gin connection with Letter and desirable, or that any reissue or extension of the that any reissue or extension of the that any reissue or extension of the that any the that and defense the that the that are that are that are that are the that are the that are th	et he said in ters y any aths, of d e on for
AND for the saignee, its success ssignee, or the couronnection with said atent for said invent vision, continuation afters Patent, to be on do all acts necessiters Patent for said isigns, but at the continued States to the see sole use and behold the said states and behold the said said said said said said said said	nsel of its successor Inventions, or said a tions in any country, or continuation-in-potation obtained thereon, is sary or required to be dinventions, without st and expense of the diassignors hereby a taid assignee as the coof of the said assigned assigned.	re, legal representative polication for Letters, including interference out of any application is lawful and desirable be done for the procut tharge to the said assignee, its request the Commission assignee of said invinee, its successors, Name of Inventor	ves and assigner, shell edves and assigner, shell edves Patent, or any proceedings proceedings, is lawful an for Letters Patent, or any pages and document, maintenance, end assignee, its successors, legal represessioner of Patents to issue rentions and the Letters Patents of the page of the pa	t, whenever counsel of the that any processing in connection with Let and desirable, or that any reissue or extension of iments, take all lawful or forcement and defense egal representatives and assigns, said Letters Patent of that ent to be issued there assigns. Yunik Chan	et he said in ters y any aths, of d e on for
AND for the saignee, its success ssignee, or the couronnection with said atent for said invent vision, continuation afters Patent, to be on do all acts necessiters Patent for said isigns, but at the continued States to the see sole use and behold the said states and behold the said said said said said said said said	nsel of its successor Inventions, or said a tions in any country, or continuation-in-potation obtained thereon, is sary or required to be dinventions, without st and expense of the diassignors hereby a taid assignee as the coof of the said assigned assigned.	re, legal representative application for Letters, including interference in the control of any application is lawful and desirable be done for the procest charge to the said assignee, its request the Commission assignee of said invince, its successors,	ves and assigner, shell edves and assigner, shell edves Patent, or any proceedings proceedings, is lawful an for Letters Patent, or any pages and document, maintenance, end assignee, its successors, legal represessioner of Patents to issue rentions and the Letters Patents of the page of the pa	i, whenever counsel of the that any processing gin connection with Let any reissue or extension of iments, take all lawful or coment and defense egal representatives and intatives and assigns. Said Letters Patent of that at the beissued there assigns. Yunik Chan	et he said in ters y any aths, of d ne on for
AND for the saignee, its success ssignee, or the couronnection with said atent for said invent vision, continuation afters Patent, to be on do all acts necessiters Patent for said isigns, but at the continued States to the see sole use and behold the said states and behold the said said said said said said said said	nsel of its successor Inventions, or said a tions in any country, or continuation-in-potained thereon, is sary or required to be dinventions, without st and expense of the dassignors hereby a said assignee as the poof of the said assigned in the said assigned i	re, legs representative application for Letters, including interference to fany application for any application of any application of any application to the procest the said assignee, its request the Commission assignee of said invenee, its successors, Name of Inventor Name of Inventor	ves and assigner, shell edvis Patent, or any proceedings, is lawful an for Letters Patent, or any proceedings, is grant of the control of the	t, whenever counsel of the that any processing in connection with Let and desirable, or that any reissue or extension of iments, take all lawful or forcement and defense egal representatives and assigns, said Letters Patent of that ent to be issued there assigns. Yunik Chan	et he said in ters y any aths, of d ne on for
AND for the ssignee, its success ssignee, or the cour connection with said atent for said invent vision, continuation etters Patent, to be do all acts necessory. AND the said signs, but at the continuation of the said states to the said states to the said states to the said states to the said states and behalf the said states to the said states and behalf the said states and behalf the said states and said states and said states are said states and said states and said states are said states and said said said said said said said sai	nsel of its successor Inventions, or said a tions in any country, or continuation-in-pobtained thereon, is sary or required to be dinventions, without st and expense of the dassignors hereby it haid assignee as the pof of the said assignor	re, legs representative polication for Letters, including interference, including interference polication of any application is lawful and desirable be done for the proct t charge to the said assignee, its request the Commission assignee of said invinee, its successors, Name of Inventor	ves and assigne, shell edvis Patent, or any proceedings, is lawful an for Letters Patent, or any proceedings, is justified and or Letters Patent, or any or, sign all papers and document, maintenance, entranssignee, its successors, legal represessioner of Patents to issue rentions and the Letters Patentions and the Le	i, whenever counsel of the that any processing gin connection with Let and desirable, or that any reissue or extension of iments, take all lawful or forcement and defense egal representatives and assigns, said Letters Patent of that ent to be issued thered assigns. Yunik Chan Dinesh C. Charles D.	et he said in ters y any aths, of d e on for
AND for the ssignee, its success ssignee, or the cour connection with said atent for said invent vision, continuation etters Patent, to be do all acts necessory. AND the said signs, but at the continuation of the said states to the said states to the said states to the said states to the said states and behalf the said states to the said states and behalf the said states and behalf the said states and said states and said states are said states and said states and said states are said states and said said said said said said said sai	nsel of its successor Inventions, or said a tions in any country, or continuation-in-pobtained thereon, is sary or required to be dinventions, without st and expense of the diassignors hereby it aid assignee as the coof of the said assign.	re, legs representative polication for Letters, including interference, including interference polication of any application is lawful and desirable be done for the proct t charge to the said assignee, its request the Commission assignee of said invinee, its successors, Name of Inventor	ves and assigner, shell edvis Patent, or any proceedings, is lawful an for Letters Patent, or any proceedings, is grant of the control of the	i, whenever counsel of the that any processing gin connection with Let and desirable, or that any reissue or extension of iments, take all lawful or forcement and defense egal representatives and assigns, said Letters Patent of that ent to be issued thered assigns. Yunik Chan Dinesh C. Charles D.	et he said in ters y any aths, of d he on for

HAR 21 89

Marie Luigs

REL 5056 RANG212



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trade ark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

TO: CIOTTI & MURASHIGE
IRRELL & MANELLA
545 MIDDLEFIELD RD., STE. 200
MENLO PARK, CA 94025

D APR 29 1988

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: 001 CHANG, YUNIK

DOC DATE: 12/16/87 DOC DATE: 12/15/87

ASSIGNOR: 002 PATEL, DINESH C. ASSIGNOR: 003 EBERT, CHARLES D.

DOC DATE: 12/15/87

RECORDATION DATE: 12/28/87 NUMBER OF PAGES 001

REEL/FRAME 4802/0996

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE: 501 THERATECH, INC., RESEARCH PARK, 410 CHIPETA WAY, SUITE 21 9, SALT LAKE CITY, UTAH 84108, A CORP. OF UTAH

SERIAL NUMBER

7-119617

FILING DATE 11/12/87

PATENT NUMBER

ISSUE DATE 00/00/00

TITLE OF INVENTION: DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SK IN OR MUCOSA

INVENTOR: 001 CHANG, YUNIK INVENTOR: 002 PATEL, DINESH C. INVENTOR: 003 EBERT, CHARLES D.

DOCKETED TEC. For 9065-0003

	Atty Dkt 9065-0003
TO THE FOR ASSI	COMMENT AND NOTE
DEC 3 IN THE UNITED STATES PAY	TENT AND TRADEMARK OFFICE
33 28	I hereby certify that this correspondence is being deposit
Application of	with the United States Postal Service as first class mail
RADE MARK	an envelope addressed to: Commissioner of Patents and fra- marks, Washington, D.C. 19231, on 23 December 1981
YUNIK CHANG et al	Group Art Unit:
Serial No.: 119,617	Examiner: Signature
Filed: 12 November 1987	Attention: Application 23 December 1987
For: DEVICE FOR ADMINISTERING)	Division Date
AN ACTIVE AGENT TO THE	
SKIN OR MUCOSA TRANSMITTAL LETTER FOR MIS	SING PARTS OF APPLICATION
Honorable Commissioner of Patent	s and Trademarks
Washington, D.C. 20231	13/11 June 20 Section
Sir:	Control of the control
In complete response t	to the Notice to File Missing
•	F.R. \$1.53(d) dated 8 December 1987,
	tion regarding change in order of
/ Invento	rship; tion and Power of Attorney signed
— a comprised peorara	and the surcharge of
·	as set forth in 37 C.F.R. \$1.16(e);
	mall Entity Status and a Request
for Refund;	mall breley beacas and a hequese
☐ a Petition for Ext	oncion of Time.
	translation of the application,
and the \$26.00 fee	as set forth in 37 C.F.R. £1.17(k);
区 an Assignment docu	ment and the \$ 7.00 Assignment
Recording Fee;	
X other Filing fee	of \$340.00 ;
🛛 a check in the amou	unt of \$ 457.00
☐ Charge \$	to Deposit Account No. 03-1952.
The Commissioner is he	reby authorized to charge any fees
under 37 C.F.R. 1.16, 1.17 and	1.21 which may be required by this
paper, or to credit any overpa	· · · · · · · · · · · · · · · · · · ·
03-1952. A duplicate copy of	this sheet is enclosed.
	Respectfully submitted,

545 Middlefield Road Suite 200 Menlo Park, CA 94025-3471 Phone 1 19:/8641 \$196127-7250

CIOTTI & MURASHIGE, IRELL & MANELLA

Thomas E. Ciotti Registration No. 21,013

ASSIGNMENT

THIS ASSIGNMENT, by	YUNIK CHANG, DINE	ESH C. PATEL and CHARLE	S D. EBERT
hereinafter referred to as the assi	gnors), residing at T	Oms River New Jorgan	
		e City, Utah	
		new and useful improvements in	
OR ADMINISTERING AN AC			
forth in an application for Let			ederation events de-
en date herewith; 🛭 bearing Se			
WHEREAS, TheraTech	. Inc.	, a corporation	duly organized under
nd pursuant to the laws of	Utah	and having its princip	al place of business at
Research Park, 410 Ch	ipeta Way, Suite 2	19, Salt Lake City, Ut	ah 84108
ssors, legal representatives and a sons, application for Letters Pated all foreign countries which manations, and continuations-in-patents, and all rights under the Inheld and enjoyed by the said as all representatives and assigns, to anted, as fully and entirely as the signment not been made. AND for the same considerations, the said assignors are the entions and the application for at the said assignors have good at the said assignors have good are in set forth.	ay be granted therefor an art of said application, ternational Convention for signee, for its own use and the full end of the term to the full end of the term to the same would have been it ation, the said assignors essentatives and assigns, to sole and lawful owners of Letters Patent above to the said assigns, the said assigns are said assigns as the said as the said assigns as the said a	or reissues or extensions of so or the Protection Of Industrial and behoof and the use and behoor terms for which Letters Patcheld and enjoyed by the assign hereby covenant and agree that, at the time of execution of the entire right, title and intersional and the contraction of the entire right, title and intersional and the contraction of the entire right, title and intersional and the contraction of the entire right, title and intersional and the contraction of the entire right, title and intersional agree that the entire right.	ted States of America and all divisions, con- aid Letters Patent or Property, the same to too of of its successors, ent or Patents may be ors, had this sale and to and with the said and delivery of these rest in and to the said
AND for the same considerate signee, its successors, legal represent assignee, or the counsel of its acconnection with said inventions it at any division, continuation or dension of any Letters Patent, to see all lawful oaths, and do all accoment and defense of Letters Patent, to real representatives and assigns, but it is a said assigns. AND the said assignors hereby	stion, the said assignors sentatives and assigns, the successors, legal represent or said application for L in any country, including a continuation-in-part of a be obtained thereon, is less necessary or required atent for said inventions, but at the cost and expenses the Commission	hereby covenant and agree that the said assignors will, who tatives and assigns, shall advise etters Patent, or any proceeding interference proceedings, is lawny application for Letters Patent awful and desirable, sign all patto be done for the procurement, without charge to the said asset of the said assignee, its successions of Patenta and assignee.	to and with the said enever counsel of the e that any proceeding and in connection with vful and desirable, or ent, or any reissue or opers and documents, ant, maintenance, en- signee, its successors, ssors, legal represen-
ited States to the said assignee, a the sole use and behoof of the			
		•	RECORDE PATENT & TRADEMA
ite 12-16-87 Name of	Inventor Oker & C	fine YUNIK CH	,
te 12-15-87 Name of	Inventor Polos	DINESH C	ULC 20

Date 12-15-87

B

PATENT Docket No. 290652802400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Yunik Chang et al.

Serial No.:

07/326,536

Filing Date:

March 21, 1989

Patent No.:

4,983,395

Issued:

January 8, 1991

For:

DEVICE FOR ADMINISTERING

AN ACTIVE AGENT TO THE SKIN OR

MUCOSA

ASSOCIATE POWER OF ATTORNEY

Assistant Commissioner for Patents
Box Patent Extension
Washington, D.C. 20231

Dear Sir:

In the matter of the above-entitled patent, please recognize the following attorneys and agents:

Thomas E. Ciotti (Reg No 21,013) Gladys H. Monroy (Reg No 32,430)

Paul Schenck (Reg No 27,253)

Freddle K. Park (Reg No 35,636)

Paul C. Kimball (Reg No 34,641)

Patricia M. Drost (Reg No 29,790)

Cecily Anne Snyder (Reg No 37,448)

Edward G. Durney (Reg No 37,611)

Gary A. Green (Reg No 38,474)

Harry J. Macey (Reg No 32,818)

David L. Bradfute (Reg No 39,117)

Laurie Axford (Reg No 35,053)

Catherine M. Polizzi (Reg No P40,130)

Kate H. Murashige (Reg No 29,959)

Debra Shetka (Reg No 33,309)

Thomas B. Wheelock (Reg No 28,825)

Susan K. Lehnhardt (Reg No 33,943)

James R. Shay (Reg No 32,062)

Shmuel Livnat (Reg No 33,949)

Tyler Dylan (Reg No 37,612) Reid G. Adler (Reg No 30,988)

Antoinette F. Konski (Reg No 34,202)

Stuart P. Kaler (Reg No 35,913)

Robert Saltzberg (Rog No 36,910)

Mani Adeli (Reg No P39,585)

Sean Brennan (Reg No P39,917)

pa-51173

Application for Patent Extension

Patent No. 4,983,395

Atty Dkt.: 290652802400

Appendix B

James C. Peacock III (Reg No P40,124)

J. Michael Schiff (Reg No P40,253)

whose address is:

Morrison & Foerster 755 Page Mill Road Palo Alto, California 94304-1018

as my associates in the above-identified application to inspect the file, to prepare and file amendments, to inspect and make copies thereof and of any papers in any appellate and inter partes proceedings in which the application or patent issued thereon may be or become involved, and generally to conduct all business in the United States Patent and Trademark Office connected therewith including the application for extension of the patent term of the patent issued thereon.

Please direct all communications concerning this matter to:

Antoinette F. Konski Morrison & Foerster 755 Page Mill Road Palo Alto, California 94304-1018

Telephone: (415) 677-6113 Facsimile: (415) 494-0792

Dated: November 21 1995

TheraTech, Inc. Assignee of Record

D. Eber-7 Title: Senier Vice President A +D

417 Wakara Way, Suite 100 Salt Lake City, Utah 84108

290652802400

CERTIFICATE UNDER 37 CFR Section 3.73(b)

Applicants: Yunik Chang, Dinesh C. Patel, and Charles D. Ebert;

For: DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA, U.S. Patent No. 4,983,395, issued January 8, 1991, filed as U.S. Application No. 07/326,536, on March 21, 1989, a continuation-in-part of U.S. Serial No. 07/119,617, filed November 12, 1987, now U.S. Patent No. 4,849,224, issued July 18, 1989;

and TheraTech, Inc. a corporation organized under the laws of the state of Delaware and having a place of business at 417 Wakara Way, Suite 100, Salt Lake City, Utah,

certifies that it is the assignee of the entire right, title and Interest in the patent identified above by virtue of:

an assignment from the inventors to TheraTech, Inc., recorded on March 21, 1989, on Reel 5056, Frame 0212, and by virtue of an assignment for U.S. Patent No. 4,849,224, recorded on December 28, 1987, on Reel 4802, Frame 0996.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:	November 21, 1995
Name:	Charles D. Ebent
Title:	Senior Vice President, Research and Development
Signature:	Chile W. Cold



UNITED STATES ARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

TO: IRELL & MANELLA
545 MIDDLEFIELD ROAD, STE. 200
MENLO PARK, CA 94025-3471

OCT 6 1989

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: OO1 CHANG, YUNIK ASSIGNOR: OO2 PATEL, DINESH C.

ASSIGNOR: 003 EBERT, CHARLES D.

DOC DATE: 03/17/89

DOC DATE: 03/16/89 DOC DATE: 03/16/89

RECORDATION DATE: 03/21/89 NUMBER OF PAGES 001 REEL/FRAME 5056/0212

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE: 501 THERATECH, INC., RESEARCH PARK, 410 CHIPETA WAY, STE. 219, SALT LAKE CITY, UT 84108, A CORP. OF UT

SERIAL NUMBER 7-326536
PATENT NUMBER

FILING DATE 03/21/89 ISSUE DATE 00/00/00

TITLE OF INVENTION: DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SK IN OR MUCOSA

INVENTOR: OO1 CHANG, YUNIK
INVENTOR: OO2 PATEL, DINESH C.
INVENTOR: OO3 EBERT, CHARLES D.

DOCKETED TEC 9065-0003 20

9065-0003.20 J



iRELL & MANELLA 545 Middleffeld Road, Suite 200 Menio Park, California 94025-3471

17/326536

APPLICATION TRANSMITTAL LETTER

Sir:			•			R.E.
						RECE
117		itted herewith for filling is the p	patent application			
of Yuni)	k Ch	nang, Dinesh C. Pat	el, Charles D). Ebert		
or <u>DEVI</u>	ICE	FOR ADMINISTERING	AN ACTIVE AGE	NT TO T	HE S	KIN ON MUCOSA
		d are:				- COURT
	X	2_ sheet(s) of forms	d F3 informal decide			
		Claim for formion priority and		(8). (3 s CERTIII	ets)	OP MAIL DIG DIV.
		Claim for foreign priority und	mr 35 U.S.C. §119/36	3 in Express	Mail" N	OF MAILING BY "EXPRESS A Mailing Label No Mal (2019) 3.7
,		- cohumus coccinita	THE GECIEFICATION	I hereby	rentit	That the Manager
l	_	certified copy of the priority of		Office to A	delve ez	Total Control of Section 1997
ι	 ∧	in Associate Power of Attorne	y.	- 0.01149 01	*** I ::: <u>-</u>	ded it and out to the end of all of all of and out to the end of a second out to the all of a second o
	□ _	verified statement(s) or	f small entity statue	(Typed or	Printed	Mame of Popular Mailing Paper of
The	decia	ration of the inventor [3] is e		Do.	10	M. Tal
The f	lee hi	as been calculated as follows		W. (Signature	of Pers	Mailing Paper or Fee)
		tsic Application Fee	•			
						\$ 340.00
		otal Claims6 minus	20 x \$	12.00	•	\$
C		dependent sims1 minus				
0		- IIIIUS		34.00	•	\$ <u>-0-</u>
		Multiple dependent claims pre	•	110.00	•	\$
		tal Application Fee (Total of A			•	\$ 340.00
F.	. If v	rerified statement of small ent	My status is enclosed	Ļ		
	,	y percent reduction of Total A 1% x E)	ppecation Fee		_	• -0 -
ŢG.	Apı	plication Fee Due (E minus F			•	•
		signment Recording Fee of \$	•		•	\$_340_00
	doc	zument enclosed.	7.00 if assignment	1	•	s7. 00
I.	TO	TAL FEE (G plus H)		7		\$ 347.00
X	A c	heck in the amount of \$34	17.00 is smarted	,	•	3 347.00
						,
· The Co		to Depor	ER ACCOUNT No. 03-19	62.		
in may be ricate copy	requir of this	ssioner is hereby authorized (led by this paper, or to credit : s sheet is enclosed.	to charge any fees un any overpayment, to	ider 37 G.F.i Deposit Aco	R. §1.: Ount N	16, 1.17 and 1.21 lo. 03-1952. A
		Masignostat Branch				

930324

Thomas E. Ciotti Registration No.: 21,013

Phone No.: 415/327-7250

ASSIGNMENT

JOINT

Attorney Docket No.

nereir	. C. I GIGII	90 (O 25 ()	e assignor), residing at	Toms R	iver, Ne	w Jer	sey; M	urray.	Uta
alt	Lake	City,	Utah a	nd <u>Salt</u>	Lake Ci	ty, Utah				
	liv ely , witne		J.							<u> </u>
	WHERE	S, the sa	d assignors	have invente	ed certain new					
FOR	ADMIN	ISTER	NG AN	ACTIVE A	AGENT TO	and useful im	proveme	nts in <u>DE</u>	VICE	
forth	in an appl	ication for	Lettere Des	and of the 11-1	IODAT TO	INE SKI	N OR	MUCOSA		
e ha	rawith:	bossion	Collet M	eur or the Our	ted States, 🖸	having an o	ath or dec	daration ex	ecuted on	even
•		. oe aring :	enai No			and file	d on	·		and
•	WHEREA	s. <u> </u>	heraTed	ch, Inc.	<u> </u>				a corporatio	on
org	anized und	er and pu	suant to the	laws of	Utah			and having	a ita asiasia	<u>.</u> .
e of	business a	Rese	arch Pa	rk, 410	Chipeta	Way, St	iite 2	219. Sa	il+ Tak	_
aina	ter referre	in se the	genine en :	04108	acquiring the outline of the control					
and and nt, a rante catio	by these gassigns, the assigns, the assigns, the assigns and the assign and the assign	presents di le entire r l all Letter and there	Patent or I	d interest in an Patents in the nd to any and	nd to the above United States all divisions, d	ementioned in of America a continuations,	e, its such the such that its inventions and fore and continue.	cessors, le , application sign countri inuations-in	gal represe fi for Letten ies which m	nts- s lay
r, and ant, a rante lor th beho s for enjoy ants, attions assig	assigns, the and any and any and any and and therefor and, or reissue Protection of and the which Lette ed by the a AND for the its success the said as and the authors have a AND for the authors have or the court or the court or the court of the court	oreaents de entire riall Letter sand thereign sond thereign sond to state the same control of the same con	o sell, assig ght, title and a Patent or I a Patent or I a Patent or I and this sell had this sell had this sell had this sell had the sell for Letters F full right end insideration, representa	d interest in all Patents in the Patents in the Patents in the and to any and aid Letters Pay the same is successors, it may be grant the said assignithe said assignithes and ase and lawful own the said assignithes and ass	nd to the above United States all divisions, of the to Patent or Patent obe held and eggl represented, as fully anoment not been gnors hereby origns, that, at the entitle sell and gnors hereby origns, that the sell and gnors hereby origns, that the sell and gnors hereby origns, that the sell and the sell and gnors hereby origns, that the sell and the sel	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the made, covenant and the time of exercise if that the same convey the second and assignors.	le, its such the legislation of	xessors, le, application pign countri inuations-ir the Internat signee, for the full end would have and with the d delivery of est in and to encumbered e manner!	gal represe n for Letten ies which m i-part of sai ional Convi its own use of the term i been held e said of these of the said d and that therein set e said	nts- s hay d en- l or
r, and in a same	assigns, the and any and therefore, or reissue Protection of and the which Lette and by the a AND for the aid as and the aid as and the aid as and the aid as and the aid invento or the count with seid said invento acts necessatent for said ut at the count at the co	oreaents do see entire r all Letter sond thereight of Indus use and b ors Patant use and o ors, legal signors a soplication good and same coal oors, legal seel of its loventions in en or continuo st and ex d assigno aid assigno aid assigno aid assigno of the	o sell, assig ght, title and ght, title and ght, title and ght, and in all an annions of strial Properties or Patents: shad this sall asideration, represents the sole afor Letters full right end insideration, or sald apply country, in atton-in-patents and to be sall as without coense of the reserved assigned	d interest in all Patents in the said assignite and lawful own Patent abovered lawful own the said assignites and assignite and descriptions of the passignites and assignites and assigni	nd to the above United States all divisions, of attent or Patent or be held and on the states and a fully and ment not been gnors hereby or igns, that, at the ners of the enternative and and another by the states and a fully and gnors hereby or igns, that the sentatives and a fully and gnors hereby or igns, that the sentatives and a fully procurement, are patent, it is successed in the sentation of Letting and assignee to the sentation of a fully procurement, and assignee he, its successed mmissioner of sid inventions; as sors, legal rep	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the imade, covenant and the time of exemples of that the same convey the second as a convey the second as a convey the second as a convey the second are any process of the Letter or papers and d maintenance, its successor ors, legal representatives a covenant to issue the Letter of the Letter of the context of the c	le, its such the legislation of	xessors, le, application in a ton a	gal represe n for Letten ies which m ies which m in-part of sai ional Convi- its own use of the term i been held e said of these of the said d and that therein set e said isel of the s iseding in with Letters that any instense of ives and igns, ont of the d thereon fo	nts- s nay d en- or
, and is an is a sign is	assigns, the and any and therefore, or reiss, the Protection of and the which Lette ed by the a AND for the said as a and the all mors have and the said invention than, to be acts neces tent for said ut at the country of the said as a said invention than, to be acts neces tent for said ut at the country of the said as a said invention than, to be acts neces tent for said ut at the country of the said its said invention than the country of the said its said invention than the country of the said its said invention than the country of the said its	presents de entire realité le entire realité le entire realité le le entire realité le le entire realité le	o sell, assig ght, title and ght, title and ght, title and ght, title and ght, and in all properties of sell and this sell assideration, represente the sole afor Letters full right end in sideration, representation, or said apply country, in atton-in-pathereon, is lettered to be sell assigned to be sell assigned assigned assigned assigned assigned.	d interest in air Patents in the same to successors, it may be granted end assignitives and assigned of the paid assigned to the paid assigned of see, its succession. Name of Inventor and Inventor I	nd to the above United States all divisions, of tent or Patent or be held and open as fully and ment not been gnors hereby or igns, that, at the ners of the enternatives and a procure process of the enternatives and a procurement, letters Patent, letters Patent, letters procurement, said assignees, its success minissioner of id inventions as sors, legal repated.	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the imade, covenant and the time of exemples of that the same convey the second as a convey the second as a convey the second as a convey the second are any process of the Letter or papers and d maintenance, its successor ors, legal representatives a covenant to issue the Letter of the Letter of the context of the c	te, its such that the control of the	xessors, le, application, application, application in the Internations in the Internations in the Internation in the Internation would have and with the delivery cost in and to encumbered e manner hand with the flever count and with the flever count at any processor to size or exters, take all lanent and depresentations are and assetters Pate to be issued in the insurance of the issued in the insurance of the issued in the insurance of the insu	gal represe in for Letten ies which in h-part of sai ional Convi its own use of the term been held e said of these is the said d and that therein set e said isel of the s iseding in with Letters that any swful oeths, ifense of ives and igns, int of the d thereon for Chang	nts-say d en-
nandiana and and and and and and and and and	assigns, the against the again	presents de entire realité le entire realité le entire realité le le entire realité le le entire realité le	o sell, assig ght, title and ght, title and ght, title and ght, title and ght, and in all control of the self and this sall and this sall and this sall and this sall and the self at the sole a for Letters if full right end in sideration, represented the sole a for Letters if full right end in sideration, and and the self and the	d interest in air Patents in the said assignithe said assignithes and assignithes the Course and assignithes and as	nd to the above United States all divisions, of tent or Patent or be held and open as fully and ment not been gnors hereby or igns, that, at the nentloned, end of the entitle of the enti	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the imade, covenant and the time of exemples of that the same convey the second as a convey the second as a convey the second as a convey the second are any process of the Letter or papers and d maintenance, its successor ors, legal representatives a covenant to issue the Letter of the Letter of the context of the c	le, its such the legislation of	xessors, le , application eign countri inuations-ir the Internations-ir the Internations eignee, for the full end would have and with the divery countries of manner hand with the never count at any proconnection was and as any area eignees entations es and assetters Pate to be issued as. Yunik Dinesh	gal represe in for Letter ies which in h-part of sai ional Conve its own use of the term been held e said of these of the said d and that it herein set e said isel of the s iseding in with Letters that any inswrul oeths, infense of ives and igns, int of the d thereon fo Chang C. Pa	nts-say dependence or he aid
nand nand nant, a rante catic or th opeho s for nee, ntions assig nee, nee, setions assig t for or all s Pa and S ta	assigns, the against the again	preaents de entire realité le entire realité le entire realité le le entire realité le	o sell, assig ght, title and a parent or los parent or los parents of series and this sell assignment of the series and this sell assignment of the sell assignm	d interest in air Patents in the said assignite and lawful own Patent abovered lawful and designation for Lawful and designation for the patent lawful and designation for the patent lawful and designation for the patent lawful and l	nd to the above United States all divisions, of tent or Patent or be held and on the states and divisions, of the end of	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the imade, covenant and the time of exemples of that the same convey the second as a convey the second as a convey the second as a convey the second are any process of the Letter or papers and d maintenance, its successor ors, legal representatives a covenant to issue the Letter of the Letter of the context of the c	le, its such the legislation of	xessors, le , application eign countri inuations-ir the Internations-ir the Internations eignee, for the full end would have and with the divery countries of manner hand with the never count at any proconnection was and as any area eignees entations es and assetters Pate to be issued as. Yunik Dinesh	gal represe in for Letten ies which in h-part of sai ional Convi its own use of the term been held e said of these is the said d and that therein set e said isel of the s iseding in with Letters that any swful oeths, ifense of ives and igns, int of the d thereon for Chang	nts-say dependence or he aid
r, and a same a	assigns, the against and any and therefore, or reissure Protection of and the which Lette duty the against a sand the against a with seld said invention with seld invention tent, to be acts necessitent for said ut at the countinuation the said the sa	presents de le entire riall Letter and therefees or extending the same operation of Industrial size and burs Patant issignors, a same operation of Industrial size of Italian or continuous and exity or red invention and exity or red invention and exity or red invention of the Italian of Italian or continuous and exity or red invention and exity or red invention of the Italian of Italian or continuous and exity or red invention of the Italian of Italian of Italian of Italian of Italian or continuous and exity or red invention of the Italian of Italian or Italian of It	o sell, assig ght, title and a Patent or I on, and in ai on a control of its or Patents or Patents or Patents in had this sail naideration, represente the sole a for Letters if full right end is ideration, representally in the control of its in the control of its in the control of its in the control of the instant of the control of the instant of the in	d interest in air Patents in the said assignithe said assignithes and assignithes the Course and assignithes and as	nd to the above United States all divisions, of the end and obe held and obe held and ment not been gnors hereby or igns, that, at the internal process of the ent nentloned, end gnors hereby or igns, that the segmentatives and entatives and entatives and entatives and estimated by igns, that the segmentatives and entatives and entatives and entatives and entatives and estimated by igns, it as the segmentation of Letters procurement, said assignee to it association of the entative and entatives and ent	ementioned in of America a continuations, s, and all right enjoyed by the atives and as: d entirely as the imade, covenant and the time of exemples of that the same convey the second as a convey the second as a convey the second as a convey the second are any process of the Letter or papers and d maintenance, its successor ors, legal representatives a covenant to issue the Letter of the Letter of the context of the c	le, its such the legislation of	xessors, le , application eign countri inuations-ir the Internations-ir the Internations eignee, for the full end would have and with the divery countries of manner hand with the never count at any proconnection was and as any area eignees entations es and assetters Pate to be issued as. Yunik Dinesh	gal represe in for Letter ies which in h-part of sai ional Conve its own use of the term been held e said of these of the said d and that it herein set e said isel of the s iseding in with Letters that any inswrul oeths, infense of ives and igns, int of the d thereon fo Chang C. Pa	nts-say den-

MAR 21 89

THE STATE OF PATENTS

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trade with Office

ASSISTANT SECRET AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

TO: CIOTTI & MURASHIGE IRRELL & MANELLA

545 MIDDLEFIELD RD., STE. 200

MENLO PARK, CA 94025

D APR 29 1888

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: OO1 CHANG, YUNIK ASSIGNOR: OO2 PATEL, DINESH C. ASSIGNOR: OO3 EBERT, CHARLES D. DOC DATE: 12/16/87
DOC DATE: 12/15/87
DOC DATE: 12/15/87

RECORDATION DATE: 12/28/87 NU

NUMBER OF PAGES 001

REEL/FRAME 4802/0996

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE: 501 THERATECH, INC., RESEARCH PARK, 410 CHIPETA WAY, SUITE 21

9, SALT LAKE CITY, UTAH 84108, A CORP. OF UTAH

SERIAL NUMBER 7-119617
PATENT NUMBER

FILING DATE 11/12/87 ISSUE DATE 00/00/00

TITLE OF INVENTION: DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SK

IN OR MUCOSA

INVENTOR: 001 CHANG, YUNIK INVENTOR: 002 PATEL, DINESH C. INVENTOR: 003 EBERT, CHARLES D.

For 9065-0003

	IN THE UNITED STATES PATENT AND TRADENARY OFFICE
DEC	
28 1987	I hereby certify that this correspondence is being deposits with the United States Postal Service as first class mail
PANE N	an envelope addressed to: Commissioner of Patents and Framerica. Washington, D.C. 20031, on 23 December 1981
	YUNIK CHANG et al) Group Art Unit:
8	Serial No.: 119,617 . Examiner: — Chimus , Wolff. Signature
F	Filed: 12 November 1987) Attention: Application 23 December 1987
F	Cor: DEVICE FOR ADMINISTERING) AN ACTIVE AGENT TO THE SKIN OR MUCOSA TRANSMITTAL LETTER FOR MISSING PARTS OF APPLICATION
	onorable Commissioner of Patents and Trademarks Vashington, D.C. 20231
S	ir:
	In complete response to the Notice to File Missing
	arts of Application Under 37 C.F.R. \$1.53(d) dated 8 December 1987,
а	ttached please find: Communication regarding change in order of Inventorship; a combined Declaration and Power of Attorney signed
	by the inventor(s) and the surcharge of \square \$55.00 \square \$110.00 as set forth in 37 C.F.R. \$1.16(e);
	a Declaration of Small Entity Status and a Request for Refund;
	a Petition for Extension of Time;
	and the \$26.00 fee as set forth in 37 C.F.R. £1.17(k);
	X an Assignment document and the \$ 7.00 Assignment
	Recording Fee;
	Other Filing fee of \$340.00
	Ta check in the amount of \$ 457.00
	Charge \$to Deposit Account No. 03-1952.
	The Commissioner is hereby authorised to charge any fees
	under 37 C.F.R. 1.16, 1.17 and 1.21 which may be required by this
	paper, or to credit any overpayment, to Deposit Account No.
	03-1952. A duplicate copy of this sheet is enclosed.
	Respectfully submitted,
	Suite 200 Menlo Park, CA 94025-3471
	800 ng 1 Nor-/8641 5196127-7250 By 1 518 June 9.00000

Thomas B. Ciotti Registration No. 21,013

ASSIGNMENT

THIS ASSIGNMENT, by	YUNIK CHANG, DINES	H C. PATEL and CHARLE	S D. EBERT
hereinafter referred to as the assi	gnors), residing atTo	ns River, New Jersey	
Murray, Utah	and Salt Lake (City, Utah,re	spectively, witnesseth:
		w and useful improvements in	•
FOR ADMINISTERING AN AC		-	
t forth in an application for Le	tters Patent of the United St	lates. D having an oath or de	claration executed on
en date herewith; 2 bearing Se			
		, a corporation of	
d pursuant to the laws of	Utah	and having its principal	al place of business of
Research Park, 410 Ch	ipeta Way. Suite 219	. Salt Lako City III	u prace or ousiness at
	-Post Maj/ Barbe 21	, said bake city, ota	an 84108
cheld and enjoyed by the said a sal representatives and assigns, to anted, as fully and entirely as the signment not been made. AND for the same consider signee, its successors, legal represents, the said assignors are the ventions and the application for at the said assignors have good are in set forth. AND for the same considerations its successors, legal repred assignee, its successors, legal repred assignee, or the counsel of its connection with said inventions at any division, continuation or the said assigner, to the all lawful oaths, and do all a rement and defense of Letters later presentatives and assigns, being a said assigner, the sole use and behoof of the	ation, the said assignors he sentatives and assigns, that sole and lawful owners of the Letters Patent above mentand full right and lawful aution, the said assignors he sentatives and assignors he sentatives and assigns, that successors, legal representation, or said application for Letter any country, including incontinuation-in-part of any continuation-in-part of any continuation-in-part of any continuation in required to the secessary or required to patent for said inventions, what at the cost and expense of said inventions as the assignment of said inventions as the assignment of said inventions.	terms for which Letters Pate id and enjoyed by the assignment at at the time of execution at the entire right, title and intertioned, and that the same are thority to sell and convey the ereby covenant and agree to the said assignors will, whe tives and assigns, shall advise ters Patent, or any proceeding terference proceedings, is law application for Letters Paterful and desirable, sign all pay be done for the procurement without charge to the said assign the said assignee, its successor of Patents to issue said Letters Patents and the Letters Patents	ont or Patents may be been, had this sale and on and with the said and delivery of these est in and to the said amended in the manner of and with the said never counsel of the that any proceeding in connection with ful and desirable, or not, or any reissue or pers and documents, at, maintenance, enlignee, its successors, sors, legal representators Patent of the
•			
ne 12-16-37 Name of	•	a a a a a a a a a a a a a a a a a a a	RECORDED
	l laventor Oker X (?)	VINITE OUT	PATENT & TRADEMARK O
ie 12-15-87 Name of	201		PATENT & TRADEMARK O ANG DEC 28 1987
te 12-15-87 Name of	201	DINESH C	PATENT & TRADEMARK (ANG DEC 28 1987 PATEL

Chang et al.

[54]	DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA				
[75]	Inventors:	Yunik Chang, Toms River, N.J.; Dinesh C. Patel, Murray; Charles D. Ebert, Salt Lake City, both of Utah			
[73]	Assignee:	TheraTech Inc., Salt Lake City, Utah			
[*]	Notice:	The portion of the term of this patent subsequent to Jul. 18, 2006 has been disclaimed.			
[21]	Appl. No.:	326,536			
[22]	Filed:	Mar. 21, 1989			

Related U.S. Application Data

[63]	Continuation-in-part	of Ser.	No.	119,617,	Nov.	12,
	1987, Pat. No. 4,849,	224.				

[31]	Int. CL'	A61F 13/U2
	U.S. Cl	
•		424/447; 424/434
[58]	Field of Search	424/448, 449, 434

[56] References Cited


U.S. PATENT DOCUMENTS
4,849,224 7/1989 Chang et al. 424/434

Primary Examiner—Merrell C. Cashion, Jr. Assistant Examiner—Leon R. Horne Attorney, Agent, or Firm—Irell & Manella

[57] ABSTRACT


A transdermal drug delivery device comprising a drug formulation-containing reservoir defined by a backing layer and a drug-permeable membrane layer, a peclable inner liner that underlies the reservoir and a portion of the backing/membrane outwardly of the reservoir periphery, an adhesive layer that underlies the inner liner and outwardly extending portions of the membrane/backing layers, and a peclable release liner layer that underlies the adhesive layer with a first permanent heat seal between the backing and the membrane about the perimeter of the reservoir and another concentric peelable (impermanent) heat seal between the membrane and the inner liner positioned underlying and at a radius not less than the first permanent heat seal, the heat seals and peclable barrier layer providing barriers that isolate the drug formulation from the adhesive.

6 Claims, 2 Drawing Sheets



Application for Patent Extension Patent No. 4,983,395 Atty Dkt.: 290652802400

Appendix C






FIG. 2




FIG.3




FIG. 4

DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of copending U.S. application Ser. No. 119,617 filed 12 Nov. 1987, now U.S. Pat. No. 4,849,224.

TECHNICAL FIELD

This invention is in the field of transdermal/ transmucosal administration of active agents (drugs). More particularly it relates to a device for achieving such administration comprising an active agent-containing reservoir and an adhesive layer for affixing the device to the skin or mucosa in which the adhesive layer is peripheral to the path of the active agent to the skin or mucosa and is protected from degradation by the components of the reservoir by a multiplicity of heat seals. ²⁰

BACKGROUND OF THE INVENTION

There are many patents describing devices for administering drugs through the skin or mucosa. These devices are commonly in the form of a laminated compos- 25 ite that includes a reservoir layer containing the drug, a pressure sensitive adhesive layer for attaching the composite to the skin, and a backing layer that forms the upper layer of the device. Depending upon the particular drug and drug formulation involved, the reservoir 30 layer may be a matrix in which the drug formulation is dispersed or a layer in the form of a walled container which holds the drug formulation. Container-type reservoirs are often formed as a pocket between the backing layer and a drug-permeable basal membrane 35 through which the drug passes to the skin. The pressure sensitive adhesive layer normally underlies the membrane and the drug also passes through it on its way to

Devices having container-type reservoirs with under- 40 lying pressure sensitive adhesive layers have significant disadvantages when one or more components of the drug formulation that are released from the reservoir to the skin are solvents for the adhesive or otherwise adversely effect the properties of the adhesive as they pass 45 through it to the skin. In such cases those reservoir component(s) cannot be permitted to pass through the adhesive and means must be found to isolate the adhesive from them. Further, in such devices the drug partitions into the adhesive and alters drug release character- 50 istics over prolonged storage. The present invention provides a device design in which the adhesive is peripheral to the path of the drug formulation and is isolated from the drug formulation by a peclable barrier disc and a multiplicity of heat seals between selected 55 layers of the device.

At least one other transdermal drug delivery device design has been proposed which involves an adhesive layer that is peripheral to the path of the drug to the skin. U.S. Pat. No. 4,573,996 describes a device that has 60 both a drug-permeable adhesive layer in the path of the drug and a peripheral drug-impermeable adhesive layer that is not in the path of the drug. The purpose of the peripheral adhesive layer is to provide a site for handling the device which avoids the risks of altering the drug path or contaminating the fingers with drug. FIG. 6 of the patent shows a multi-layer laminated composite composed of (1) a backing layer, (2) a drug permeable

membrane underlying the backing that forms with the backing a pocket that serves as a drug-containing reservoir, (3) a drug-permeable adhesive layer directly underlying the membrane, (4) a ring-shaped drugimpermeable adhesive layer adjacent and peripheral to the drug-permeable adhesive layer, and (5) a basal removable protective layer. The combination of a heat seal between the backing and the membrane at the edge of the reservoir and the peripheral drug-impermeable adhesive layer prevents radial or horizontal migration of the drug from the reservoir. This patented device is distinct from the device of the present invention in several respects. The patented device does not involve the problem of keeping drug formulation components isolated from the adhesive layer. In the patented device, the drug passes through the drug-permeable adhesive layer. There is only a single heat seal shown in the patented device. And, the single heat seal is not used to isolate the drug formulation from either adhesive layer.

The present invention is also unique in that it employs two peelable layers, a permanent heat seal and a peelable heat seal in a manner that permits the creation of a peripheral ring of adhesive when the two peelable layers are removed from the device.

DISCLOSURE OF THE INVENTION

The invention is a device for administering an active agent to the skin or mucosa of an individual comprising a laminated composite of:

(a) a backing layer;

(b) an active agent-permeable membrane, the backing layer and membrane defining

- (c) a reservoir therebetween that contains a formulation of the active agent, said reservoir having a smaller periphery than the backing layer and membrane such that a portion of the backing layer and membrane extends outwardly of the periphery of the reservoir;
- (d) a first peelable active agent formulation-impermeable layer that underlies the reservoir and a portion of said outwardly extending portion of the backing layer and membrane;
- (e) an adhesive layer that underlies and covers the first peelable active agent formulation-impermeable layer and said outwardly extending portion of the backing layer and membrane;
- (f) a second peclable active agent formulationimpermeable layer that underlies and covers the adhesive layer;
- (g) a permanent heat seal about the periphery of the reservoir between the backing layer and the membrane; and
- (h) a peelable heat seal between the membrane and the first peelable active agent formulationimpermeable layer located underneath and at a radius not less than that of the permanent heat seal, said permanent and peelable heat seals providing barriers to migration of components of the active agent formulation from the reservoir into the adhesive layer and said first and second peelable active agent impermeable layers being bonded together such that when the second peelable layer is removed from the device the peelable heat seal is broken and the first peelable layer and underlying portion of the adhesive layer is removed therewith.

FIG. 1 is an enlarged sectional view of one embodiment of the invention.

FIG. 2 is an enlarged sectional view of the embodiment of FIG. 1 after the second and first peelable layers have been peeled off the remainder of the embodiment.

FIGS. 3 and 4 are enlarged sectional views of a portion of other embodiments depicting alternative means for affixing the first and second peelable layers together. 10

The drawings are not to scale and like parts are referred to by like reference numerals in the various figures.

MODES FOR CARRYING OUT THE INVENTION

The drawing shows a device, generally designated an embodiment of the invention that is designed to administer a formulation of a drug and/or a permeation enhancer that is a solvent for pressure sensitive adhesives 20 that are commonly used in transdermal delivery devices. Device 11 is designed to place the adhesive out of the path of the enhancer-drug formulation and to prohibit radial or horizontal migration of the drug/enhancer into the adhesive. Device 11 is a laminated com- 25 posite. The uppermost layer of the composite is a heatsealable backing film 12 having an inverted, cup-shaped recess 13 that serves as a container or reservoir for a drug-enhancer formulation 14. Underlying the reservoir and all or a portion of the part of the backing layer 30 outwardly of the reservoir is a membrane layer 16 that is permeable to the drug-enhancer formulation. An inner peel sealable liner 20 underlies the membrane layer and extends outwardly of the periphery of the reservoir. The next layer in the composite is a pressure- 35 sensitive adhesive layer 15 that underlies the inner peel sealable liner and the portion of the backing layer that extends outwardly of the edge of the liner. Finally a peclable adhesive release liner layer 17 covers the entire underside of the assembly and forms the basal surface of 40 the device. There are a minimum of two concentric heat seals in the composite. The first is at 18 between the membrane and the backing. It extends completely around the perimeter of the reservoir and forms a permanent seal between the backing film and membrane. 45 The second is at 19 and is between the outer edge of the inner peel sealable liner and the membrane and forms a peclable (impermanent) seal between the membrane and inner liner. It is underneath the first heat seal and at a radius not less than that of the first heat seal. Alterna- 50 tively, it may be located vertically in line with the first heat seal, but in no event should it lie inwardly of the first heat seal. These seals prevent the drug/enhancer formulation from migrating into the adhesive during storage. After the release liner is removed, the first heat 55 seal prevents such migration during wearing. The width of the seals will usually be in the range of 0.05 cm to 1.0 cm. The peel strength between the adhesive layer and the release liner layer is greater than the force required to break the peciable seal at 19. Thus, when the release 60 liner is peeled from the underside of the assembly the peclable seal is broken and the adhesive layer peripheral to the inner peel scalable liner is cut by the edge of that liner as the release liner and peel sealable liner 20 are removed, leaving the portion of the adhesive between 65 liners 17 and 20 and creating a peripheral ring of adhesive underlying the membrane and backing peripheral to the reservoir (see FIG. 2). Alternatively, the release

depict such alternative bonding means. These means are also described in Examples 5 and 6, infra. In FIG. 3 the means is a metal staple 21 that passes vertically through the first peelable layer 20, the underlying adhesive layer 15 and the second peelable (release) layer 17 just inwardly of the edge of layer 20. Correspondingly, in FIG. 4 the means is a plastic rivet 22 that is similarly

passed through the three mentioned layers.

When device 11 is placed into use, the release liner layer 17 and inner liner 20 are peeled away from the underside of the device and discarded. This operation directly exposes the undersurfaces of the membrane and the peripheral ring of adhesive layer and the device can be placed on a desired site on the skin or mucosa of the individual to be treated with the active agent.

In the embodiment shown in FIGS. 1 and 2 the second impermeable heat seal is formed between the membrane and inner liner. It will be appreciated in this regard that additional heat-sealable layers could be included in the device between any of the component layers that are part of the membrane, backing or inner liner, as the case may be.

The invention device is useful when one or more of the components of the active agent formulation is incompatible with available adhesives that are useful for removably attaching elements to the skin or mucosa. The term "incompatible" is intended to mean that through physical and/or chemical interaction of the component(s) with the adhesive the adhesiveness or other desirable properties (e.g., nonirritancy) of the adhesive are significantly destroyed or impaired. The drug itself may be such a component or a carrier, solvent, skin permeation enhancing agent or other additive may be such a component. Also, this design prevents migration of drug into the adhesive which otherwise alters drug release characteristics over prolonged storage.

The backing layer 12 of the device may be composed of a single film or a plurality of films. In any event, its inner surface must be capable of being heat sealed to the membrane. One or more of the films that constitute the layer will be impermeable to components of the drug formulation contained in the reservoir. Examples of materials used as backing layers in transdermal delivery devices that may find use in the present invention are polyethylene, polypropylene, polyethylene vinylacetate, polyethylene terephthalate, and combinations thereof. The layer may include one or more metal layers and/or one or more fibrous layers.

The reservoir pocket in the backing may be formed by vacuum forming or other like methods of forming desired shapes in films.

The term "drug" as used to describe the principal active ingredient of the device intends a biologically active compound or mixture of compounds that has a therapeutic, prophylactic or other beneficial pharmacological and/or physiological effect on the wearer of the device. Examples of types of drugs that may be used in the invention device are antiinflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, antidepressants, antipsychotic drugs, tranquilizers, antianxiety drugs, narcotic antagonists, antiparkinsonism agents, cholinergic agonists, anticancer drugs, immunosuppression agents, antiviral agents, antibiotic agents, appetite

á

suppressants, antiemetics, anticholinergics, antihistamines, antimigraine agents, coronary, cerebral or peripheral vasodilators, hormonal agents, contraceptive agents, antithrombotic agents, diuretics, antihypertensive agents, cardiovascular drugs, and the like. The 5 appropriate drugs of such types are capable of permeating through the skin either inherently or by virtue of treatment of the skin with a percutaneous absorption enhancer. Because the size of the device is limited for patient acceptance reasons, the preferred drugs are 10 those that are effective at low concentration in the blood stream. Examples of specific drugs are steroids such as estradiol, progesterone, norgestrel, levonorgestrel, norethindrone, medroxyprogestrone acetate, testosterone and their esters, nitro-compounds such as 15 nitroglycerine and isosorbide nitrates, nicotine, chlorpheniramine, terfenadine, triprolidine, hydrocortisone, oxicam derivatives such as piroxicam, ketoprofen, mucopolysaccharidases such as thiomucase, buprenorphine, fentanyl, naloxone, codeine, dihydroergotamine, 20 pizotiline, salbutamol, terbutaline, prostaglandins such as misoprostol and enprostil, omeprazole, imipramine, benzamides such as metoclopramine, scopolamine, peptides such as growth releasing factor and somatostatin, clonidine, dihydropyridines such as nifedipine, verapa- 25 mil, ephedrine, pindolol, metoprolol, spironolactone, nicardipine hydrochloride, calcitriol, thiazides such as hydrochlorothiazide, flunarizine, sydononimines such as molsidomine, sulfated polysaccharides such as heparin fractions and the salts of such compounds with phar- 30 maceutically acceptable acids or bases, as the case may

Depending upon the inherent permeability of the skin to the particular drug or drugs being administered by the device, the reservoir may also contain a percutaneous absorption enhancer that increases the permeability of the skin to the drug(s) and is coadministered to the skin. Examples of percutaneous absorption enhancers are those referred to in U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616, 4,060,084, and 4,379,454 and J 40 Pharm Sci (1975) 64:901-024. The formulation contained in the reservoir may also include solvent(s), gelling agents, stabilizers, and other additives. As indicated previously one or more of these components or a combination of these components is incompatible with the 45 adhesive.

The membrane is permeable to the drug. It may be a "dense" membrane made of a material that is inherently permeable to the components of the reservoir that are to be administered to the skin or mucosa or it may be made 50 of a microporous material whose pores are filled with a drug-permeable material including the drug-enhancer formulation itself. In the case of dense membranes, the component(s) dissolve in the material and diffuse through the material to the skin. In the case of microporous materials the component(s) diffuse through the pores to the skin. The membrane may or may not be a rate-controlling element depending upon the particular drug involved, the permeability of the skin to the drug, and the rate of delivery required to provide therapy. 60 Examples of materials for making dense membranes are given in U.S. Pat. Nos. 3,598,122 and 4,650,484. Examples of materials for making microporous membranes are provided in U.S. Pat. Nos. 3,797,494 and 4,031,894.

The adhesive layer is composed of a pressure sensitive surgical adhesive such as those that are commonly used to affix transdermal drug delivery devices, bandages or other dressings to the skin. Examples of such

adhesives are polyisobutene, natural rubber adhesives, acrylic and methacrylic adhesives, and silicone adhesives.

The release liner layer 17 and inner liner 20 may be composed of a single layer or a multiplicity of layers. They should be (1) impermeable to the components of the drug formulation that diffuse through the membrane, (2) heat-sealable in the case of the inner liner, and (3) inherently strippable or peelable or rendered so by techniques such as silicon or fluorocarbon treatment or surface treatment with a seal incompatible layer. An example of a film having such properties is Bertek 4418 Peelable Seal.

The respective components of the device may be formulated and assembled using procedures that are known in the drug formulation, transdermal device, and laminating arts. The shape of the device is not critical, and devices of preformed shapes may be assembled directly or punched, cut, or otherwise formed from large sheets of laminated composite.

The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner.

EXAMPLES

Example 1

A silicone adhesive is prepared by mixing Dow Corning 355 Medical Adhesive with Dow Corning 360 Medical Fluid (10,000 cps) to provide 20% (wt/wt) Medical fluid in the final adhesive. The adhesive/medical fluid mixture is coated onto an Akrosil Biorelease release liner using a 10 mil gap casting knife and the adhesive solvent is evaporated at 80° C. for 15 min to provide a final dry adhesive coating thickness of 0.0025 inches. A peelable heat seal disc (Bertek 4418) is then die cut into a 1.375 inch diameter circular disc which is positioned onto the adhesive surface of above adhesivecoated release liner with the peelable heat seal surface facing outward. A 0.002 inch thick microporous membrane (3M, MSP-61588) is then laminated over the entire surface of the above adhesive/release liner/peelable disc structure to form a membrane/peelable disc/adhesive/release liner laminate (L1).

The backing film (Scotchpak 1012) is pressure formed to provide a 5 cm² surface area and a 0.4 cc volume circular shaped cup.

A gelled calcitriol/enhancer reservoir formulation is prepared by mixing sufficient amounts of calcitriol and Klucel HF ® with a 67.5%/21.75%/7.5%/3.25% (volume percent) mixture of ethanol/water/glycerine/methyl laurate to provide a 100 ug/ml calcitriol concentration and a 1.5% Klucel HF © gel.

To fabricate a clacitriol system, 0.4 ml of the gelled calcitriol formulation is pipetted onto the microporous membrane surface of the L1 laminate coinciding with the exact center of the peelable disc underlying the membrane. The backing film is then placed over the L1 laminate such that the pre-formed cup on the backing film is situated over the drug/enhancer gel. The backing film is then heat sealed to the L1 laminate using a 0.9934 inch diameter circular heat seal die with a 0.0787 inch width heat sealing zone at 320° C. with 30 PSI pressure for 0.5 seconds. The single heat sealing step creates the permanent heat seal between the backing film and microporous membrane layers, and simultaneously forms the peelable seal between the micropo-

rous membrane and the peclable disc directly underneath the permanent seal.

The backing film is then sealed to the microporous membrane in the outer area peripheral to the drugenhancer reservoir with a heated plate. Finally, a 20 5 cm² (overall surface area) calcitriol system is die cut from the heat sealed structure using a steel rule die.

The peel force between the silicone adhesive and the release liner is greater than the force necessary to break the peclable seal between the membrane and the pecl- 10 able disc. Therefore, when the release liner is peeled the release liner exposing the 5 cm² microporous membrane drug-enhancer delivery surface area and creating the peripheral adhesive pattern. The in vitro steady state calcitriol skin flux is determined using the methods of 15 Merritt and Cooper (J. Controlled Release 1:161, 1984) to be 1 ug/cm²day.

Example 2

A membrane/peelable disc/adhesive/release liner 20 laminate (L1) is prepared as described in Example 1 using a Scotchpak 1022 release liner in place of the Akrosil Biorelease release liner.

A pindolol-enhancer gel formulation is prepared by mixing adequate quantities of pindolol HCl and Klucel 25 mixture consisting HF(R) with 50%/39%/10%/1% (volume percent) ethanol/water/glycerine/glycerol monooleate to provide a gel with a final pindolol concentration of 65 mg/cc and Klucel level of 1.5% (wt/wt).

The pindolol-enhancer gel is pipetted (0.4 ml) onto the L1 laminate and a Scotchpak 1012 backing film (0.4 ml cup previously formed) is positioned over the laminate. The backing film is then heat sealed to the L1 laminate and a final system is die cut as described in 35 Example 1. When the release liner is peeled from the system, the peel force between the adhesive and release liner is greater than the force necessary to break the peclable seal between the peclable disc and the microporous membrane. The peclable disc is thus removed 40 from the system with the release liner, creating the peripheral adhesive and exposing the drug-enhancer delivery surface area. The in vitro pindolol skin flux from the system is determined using the methods of Merritt and Cooper, supra, to be 33 ug/cm²/hr.

Example 3

An L1 laminate is prepared as described in Example l using a polyisobutylene (PIB) adhesive in place of the silicone adhesive and a Daubert C-150 release liner in 50 place of the Akrosil Biorelease release liner. A nicardipine-enhancer gel formulation is prepared by mixing adequate quantities of nicardipine HCl and Klucel HF® with a 65%/10%/20%/5% (volume percent) mixture of ethanol/ water/glycerine/glycerol mono- 55 composite of: oleate to provide a final gel with a nicardipine concentration of 150 mg/cc and a Klucel level of 1.5% (wt/wt). A nicardipine transdermal system is then prepared as described in Example 1 using the nicardipineenhancer gel formulation.

As with the previous examples, the peel force between the PIB adhesive and the release liner is greater than the force necessary to break the peciable seal between the microporous membrane and the peclable disc. As such, the peclable disc is removed with the release 65 liner when the release liner is peeled away from the system, simultaneously creating the peripheral adhesive pattern. The in vitro skin flux from the nicardipine

system is determined using the methods described above to be 15 ug/cm²/hr.

Example 4

The L1 laminate is prepared as described in Example 1 using 3M #93088 medical grade acrylic adhesive in place of the silicone adhesive and a silanized release liner in place of the Akrosil Biorelease release liner.

Prior to laminating the microporous membrane, the disc is fastened to the underlying release liner by using a sewing needle with a nylon thread. The needle with the nylon thread is pushed through the disc at a distance of 0.0469 inches from its peripheral edge through the underlying adhesive and release liner. This procedure is repeated in the opposite direction by first piercing the release liner followed by the disc 0.1875 inches removed from the first stitch, while still maintaining 1 mm distance to the edge of the disc. The nylon thread is pulled tight and the two ends are tied to each other forming a knot as close to the surface of the disc as possible. This stitch forms the mechanical bond between the disc and the release liner.

The 0.002 inch thick microporous membrane (3M MSP-61588) is then laminated over the entire surface of the above peclable disc/adhesive/release liner structure to form a membrane/peelable disc/adhesive/release liner laminate. This structure is used to fabricate calcitriol, pindolol and nicardipine transdermal systems as described in Examples 1, 2 and 3.

Example 5

An L1 laminate is prepared as described in Example 4 except that a mechanical bonding of the disc to the release liner is obtained by stapling the disc to the release liner. The disc is stapled 0.030 of an inch removed from the peripheral edge of the disc to the release liner by using a 0.375 inch long metal staple. Calcitriol, pindolol and nicardipine transdermal systems are then prepared as described in Examples 1, 2 and 3.

Example 6

An L1 laminate is prepared as described in Example 4 except that the mechanical bond is obtained by the use of a plastic rivet. This rivet is formed by first punching 45 a 0.020 inch diameter hole into the disc/ adhesive/release liner laminate. The center of this hole is 0.030 inches set back from the edge of the disc.

A thermoset polymer is then extruded into this hole and forms a mechanical bond upon cooling.

Transdermal systems are then prepared from this L1 laminate as described in the previous examples.

What is claimed is:

- 1. A device for administering an active agent to the skin or mucosa of an individual comprising a laminated
 - (a) a backing layer;
 - (b) an active agent-permeable membrane, the backing layer and membrane defining
 - (c) a reservoir therebetween that contains a formulation of the active agent, said reservoir having a smaller periphery than the backing layer and membrane such that a portion of the backing layer and membrane extends outwardly of the periphery of the reservoir;
 - (d) a first peelable active agent formulation-impermeable layer that underlies the reservoir and a portion of said outwardly extending portion of the backing layer and membrane;

- (e) an adhesive layer that underlies and covers the first peelable active agent formulation-impermeable layer and said outwardly extending portion of the backing layer and membrane;
- (f) a second peelable active agent formulationimpermeable layer that underlies and covers the adhesive layer;
- (g) a permanent heat seal about the periphery of the reservoir between the backing layer and the mem- 10 brane; and
- (h) a peelable heat seal between the membrane and the first peelable active agent formulation-impermeable layer located underneath and at a radius not less than that of the permanent heat seal, said permanent and peelable heat seals providing barriers to migration of components of the active agent formulation from the reservoir into the adhesive layer and said first and second peelable active agent impermeable layers being bonded together such that when the second peelable layer is removed from the device the peelable heat seal is

broken and the first peelable layer and underlying portion of the adhesive layer is removed therewith.

- 2. The device of claim 1 wherein the adhesive is incompatible with one or more of the components of the formulation that permeate through the membrane to the skin or mucosa.
- 3. The device of claim 1 wherein the backing layer is a laminated composite of at least one layer that is impermeable to the formulation and an inner heat-sealable layer.
- 4. The device of claim 1 wherein the adhesive is an acrylic adhesive, the active agent is pindolol hydrochloride, and the formulation includes ethyl alcohol and glycerol monooleate.
- 5. The device of claim 1 wherein the adhesive is an acrylic adhesive, the active agent is nicardipine hydrochloride, and the formulation includes ethyl alcohol and glycerol monooleate.
- 6. The device of claim 1 wherein the adhesive is a silicone adhesive, the active agent is calcitriol and the formulation includes ethanol, methyl laurate, and water.

25

30

35

40

45

50

55

60



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D. C. 20231 Address:

PAYOR NUMBER 000197

75L4/0824

COMPUTER PATENT ANNUITIES C/O COMPUTER PATENT ANNUITITES, INC. 1111 JEFFERSON DAVIS HIGHWAY SUITE 514, CRYSTAL GATEWAY NORTH ARLINGTON, VA 22202

DATE MAILED 08/24/94

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 10, "status" below.

If a maintenance fee payment is defective, the reason is indicated by code in column 10, "status" below. An explanation of the codes appears on the reverse of the Maintenance Fee Statement. TIMELY COR-RECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(k) and (I).

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

ITM NBR	PATENT NUMBER			SUR CHARGE	SERIAL NUMBER	PATENT DATE	FILE DATE	PAY SML YR ENT	
1	4,983,395	183	930		07/326,536	01/08/91	03/21/89	04 NO	PAID

If the "status" column for a patent number listed above does not indicate "PAID" a code or an asterisk (*) will appear in the "status" column. Where an asterisk (*) appears, the codes are set out below by the related item number. An explanation of the codes indicated in the "status" column and as set out below by the related item number appears on the reverse of the maintenance fee statement.

> ITM NBR

ATTY DKT NUMBER

9065000320

DIRECT THE RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO: COMMISSIONER OF "ATENTS AND TRADEMARKS, BOX M. FEE, WASHINGTON, DC 20231 Application for Patent Extension Patent No. 4,983,395 Atty Dkt.: 290652802400

Appendix D

MAINTENANCE FEE STATEMENT STATUS CODES AND DEFINITIONS

	·
CODE	DEFINITION
	IN REGARD TO THE MAINTENANCE FEE PAYMENT(S)
F160	The maintenance fee has already been paid. A refund of the payment has been scheduled to be sent to the fee address of record.
F161	The maintenance fee payment will not be accepted because it has been tendered too early. See 37 CFR 1.362. A refund of the payment has been scheduled.
F162	The maintenance fee payment does not properly identify the patent for which payment is to be made in accordance with 37 CFR 1.366(c). Either the U. S. application serial number or the patent number has been omitted. Both numbers are necessary to ensure proper crediting of the maintenance fee to the desired patent.
F163	The maintenance fee payment based upon certificate of mailing procedures is untimely, since it is not in compliance with the requirements of 37 CFR 1.8.
F164 .	The maintenance fee payment based upon "Express Mail" procedures is untimely since it is not in compliance with the requirements of 37 CFR 1.10.
F165	The maintenance fee and surcharge payment are not accepted because they have been submitted with the payment of fees for other purposes. See 37 CFR 1.366(e). A refund of the payment has been scheduled.
F166	The maintenance fee payment is not accepted because it is not immediately negotiable in the United States for the full payment of the required fee. Payment should be made in U. S. specie, Treasury notes, national bank notes, post office money orders or by certified check. See 37 CFR 1.23. The payment is returned herewith.
F167	The check or deposit account authorization is not accepted because it is unsigned. It is returned herewith.
F168	The payment received or the balance in the deposit account authorized for payment is insufficient to cover payment of the maintenance fee and surcharge, if any. Any payments accepted have been applied in accordance with the provisions of 37 CFR 1.366(e).
F169	The payment is in excess of the amount required. A refund has been scheduled.
	IN REGARD TO THE STATEMENT OF SMALL ENTITY STATUS
E180	A signature to the small entity statement is omitted.
E181 ~	A small entity statement from each joint inventor has not been received.
E182	A small entity statement from the assignee or licensee has not been received.

A small entity statement from the assignee or licensee has not been received.

The small entity statement was not verified by an oath or a declaration.

The requirements for filing as an independent inventor have not been met. See 37 CFR 1.9(c).

The requirements for filing as a small business concern have not been met. See 37 CFR 1.9(d).

The requirements for filing as a nonprofit organization have not been met. See 37 CFR 1.9(e).

E183

E 184

E185

E186

E

Delua a Shela

to entite that this accessor is made below.

grand and the second

Atty Dkt:

9065-0003.20

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

YUNIK CHANG et al.

Serial No.: 07/326,536

Group Art Unit: 158

Filed: 21 March 1989

Examiner: L. Horne

For: DEVICE FOR ADMINISTERING AN

ACTIVE AGENT TO THE SKIN OR

MUCOSA

TERMINAL DISCLAIMER

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

TheraTech, Inc., having an address at Research Park, 410 Chipeta Way, Suite 219, Salt Lake City, Utah 84108, U.S.A., is the assignee of all right, title, and interest in the above-captioned application, Serial No. 07/326,536, filed 21 March 1989, for "DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA" by virtue of an assignment recorded 21 March 1989 on Reel 5056, Frame 0212, and of U.S. Patent Number 4,849,224, filed 12 November 1987, directed to "DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA", by virtue of an assignment recorded 28 December 1987, on Reel 4802, Frame 0996.

TheraTech, Inc. hereby disclaims the terminal part of any patent granted on the subject patent application which would extend beyond 18 July 2006, the term of United States Patent No. 4,849,224, and hereby agrees that any

patent so granted on said application shall be enforceable only for and during such period that legal title to said patent shall be the same as legal title to United States Patent No. 4,849,224; this agreement to run with any patent granted on the subject patent application and to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the subject patent application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of United States Patent No. 4,849,224 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully submitted,

THERATECH, INC.

By: DINESH C PATE

Title: PRESIDENT

Date: 3/8/90

das/90.65-0003/20/termdiscl

Date	SubjectiMatter	Àctivity	Comments
11/28/89	IND	Submission to	Submission by TheraTech of
		FDA	IND pursuant to Section 505(i)
11/28/89	IND	IND received	IND received by FDA
12/01/89	IND	Letter from FDA	Receipt of IND acknowledged and IND # 34,028 assigned
01/25/90	IND	FDA letter	Request for additional information
08/20/90	IND	FDA letter	Request for formal submission o f01/20/90 FDA request for additional information
06/14/91	IND	FDA letter	FDA's comments relation to chemistry portion of submission
09/28/94	NDA 20-489	NDA 20-489 original submission	Submission under Section 505(b) for product Androderm®
10/5/94	NDA 20-489	Letter from FDA	Acknowledge receipt on 9/30/94 of NDA application and provides reference No. NDA 20-489
12/20/94	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission
03/02/95	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission
03/30/95	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission
03/31/95	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission
04/24/95	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission

05/12/95	NDA 20-489 Amendment	Submission to FDA	Supplemental Submission
05/31/95	NDA 20-489 Amendment	Letter from FDA	Acknowledges review of Manufacturing/Quality Controls Section of submission and requests additional information and amendments to physician package insert for product
06/22/95	NDA 20-489	Submission to FDA	Supplemental Submission
08/16/95	NDA 20-489	Submission to FDA	Supplemental Submission
08/22/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/01/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/07/95	NDA 20-489	Letter from FDA	Requests clarification to proposed logo for Androderm®; requests use of identifier MACMIS ID # 3524 in future correspondence
09/15/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/20/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/22/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/25/95	NDA 20-489	Submission to FDA,	Supplemental Submission
09/27/95	NDA 20-489	Submission to FDA	Supplemental Submission
09/29/95	NDA 20-489	Letter from FDA	FDA APPROVAL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Yunik Chang et al.

Serial No.:

07/326,536

Filing Date:

March 21, 1989

Patent No.:

4,983,395

Issued:

January 8, 1991

For:

DEVICE FOR ADMINISTERING

AN ACTIVE AGENT TO THE SKIN OR

MUCOSA

DECLARATION

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231

Dear Sir:

The undersigned, attorney for TheraTech, Inc. in connection with the application for patent term extension, which is the Applicant for Extension of Patent Term under 35 U.S.C. Section 156 with regard to U.S. Patent No. 4,983,395, hereby declares that:

- 1. I am an attorney authorized to practice before the United States Patent and Trademark Office and have general authority to act on behalf of the owner in connection with the application for patent term extension submitted herewith for U.S. Patent No. 4,983,395.
- 2. I have reviewed and understand the contents of the application being submitted pursuant to 35 U.S.C. Section 156 and 37 C.F.R. Section 1.740.

- 3. I believe the patent is subject to extension pursuant to 35 U.S.C. Section 156 and 37 C.F.R. Section 1.710.
- 4. I believe an extension of the length claimed is justified under 35 U.S.C. Section 156 and the applicable regulations.
- 5. I believe the patent of which the extension is being sought meets the conditions for extension of patent term as set forth in 37 C.F.R. Section 1.720.
- 6. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any extension of patent term issued thereon.

Dated: November 22, 1995

Respectfully submitted,

By:

Antoinette F. Konski Registration No. 34,202

Morrison & Foerster 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (415) 813-5730 Facsimile: (415) 494-0792